샘플 요청 목록

 카트 문의
시장보고서
상품코드
1737375

세계의 건선성 관절염 치료 시장

Psoriatic Arthritis Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 452 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

건선성 관절염 치료 세계 시장은 2030년까지 163억 달러에 달할 전망

2024년에 108억 달러로 추정되는 건선성 관절염 치료 세계 시장은 2024-2030년 분석 기간에 CAGR 7.1%로 성장하여 2030년에는 163억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 생물학적 제제는 CAGR 6.3%를 기록하며 분석 기간 종료시에는 95억 달러에 달할 것으로 예상됩니다. 비생물학적 제제 부문의 성장률은 분석 기간 동안 CAGR 8.1%로 추정됩니다.

미국 시장은 29억 달러로 추정, 중국은 CAGR 11.0%로 성장 예측

미국의 건선성 관절염 치료 시장은 2024년에 29억 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 34억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.0%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 3.6%와 6.9%로 예측됩니다. 유럽에서는 독일이 CAGR 4.7%로 성장할 것으로 예측됩니다.

세계의 건선성 관절염 치료 시장 - 개별화된 자가면역 케어 시대는 도래할까?

질병에 대한 인식 제고로 조기 진단 및 조기 치료 촉진?

건선과 관련된 만성 염증성 질환인 건선성 관절염(PsA)은 사회적, 임상적 인식의 향상으로 인지도가 높아지고 있습니다. 과거에는 과소 진단되거나 오진되었던 PsA가 이제는 조기에 발견되어 적시에 치료 개입이 이루어지고 더 나은 결과를 가져오고 있습니다. 의료 기관, 피부과, 류마티스 학회 등의 홍보 캠페인이 증가함에 따라 환자들에게 관절의 불편함이나 뻣뻣함을 조기에 보고할 것을 촉구하고 있습니다. 영상 진단 및 바이오마커 검사의 혁신은 진단의 정확성을 높이고, 환자 지원 커뮤니티는 환자들의 적극적인 치료를 위한 행동을 독려하고 있습니다. 이러한 요인들은 질병의 진행과 삶의 질을 결정하는 중요한 요소인 조기 치료 시작을 촉진하고 있습니다.

생물학적 제제와 표적 치료제가 치료 상황을 바꿀 수 있을까?

TNF 억제제, IL-17 억제제, IL-23 억제제, JAK 억제제 등 생물학적 제제와 저분자 억제제의 등장으로 PsA 치료 시장은 급격한 변화를 겪었으며, TNF 억제제, IL-17 억제제, IL-23 억제제, JAK 억제제가 일차 치료제로 등장하여 보다 표적화된 면역 조절을 통해 효능을 개선하고 전신적인 부작용을 감소시켰습니다. 생물학적 제제의 가격이 더 저렴해지고 바이오시밀러가 시장에 진입함에 따라 다양한 지역에서 접근성이 확대되고 있습니다. 또한, PDE4 억제제와 같은 경구용 치료제는 주사 가능한 생물학적 제제를 사용하고 싶지 않거나 사용할 수 없는 환자들에게 보다 편리한 치료 옵션을 제공하고 있습니다. 임상 가이드라인은 관절 손상을 예방하기 위해 조기에 생물학적 제제를 사용하는 것을 지지하고 있으며, 이는 첨단 치료법에 대한 수요를 더욱 증가시키고 있습니다.

환자 중심 치료는 치료의 맞춤화를 촉진하는가?

건선성 관절염은 환자마다 증상이 다르기 때문에 개별화된 치료 전략이 중요합니다. 류마티스 진료에서는 환자와 의료진이 협력하여 동반질환, 라이프스타일 선호도, 치료 목표에 따라 치료법을 선택하는 공동 의사결정이 보편화되어 있습니다. 디지털 헬스 툴은 증상, 복약 순응도, 약물 치료에 대한 반응을 추적하고 실시간으로 치료 계획을 조정하는 데 도움을 주고 있습니다. 또한, 환자들은 잠재적인 부작용, 접근 프로그램, 대체 치료법에 대한 지식을 넓혀가고 있습니다. 개별화된 치료로의 전환과 접근성 지원 서비스의 개선은 치료의 만족도와 지속성을 높이고, 다양한 치료 제공에 대한 수요를 강화하고 있습니다.

건선성 관절염 치료 시장의 성장은 몇 가지 요인에 의해 주도됩니다 ...

건선성 관절염 치료제 시장의 성장은 치료법 혁신, 광범위한 진단, 환자 참여 역학 변화 등 여러 요인에 의해 주도되고 있습니다. 기술적으로는 새로운 생물학적 경로와 경구용 약물의 개발로 인해 더 높은 효능과 특이성을 가진 치료 옵션이 확대되고 있습니다. 류마티스 클리닉과 전문 약국에서는 연계 진료 및 보험 내비게이션 서비스를 제공하는 최종 사용처의 성장이 관찰됩니다. 소비자 트렌드는 디지털 헬스 툴의 사용 확대, 임상시험 참여 등 정보에 기반한 적극적인 질병 관리로 변화하고 있습니다. 또한, 자가면역질환 치료제 파이프라인에 대한 제약사들의 투자 증가, 신흥국 시장에서의 유병률 증가, 상환제도 강화 등이 PsA 치료제의 세계 확대를 견인하고 있습니다.

부문

약물 종류별(생물학적 제제, 비생물학적 제제, 병용요법), 제품 유형별(처방약, 시판약), 투여 경로별(비경구제, 경구제), 판매 채널별(병원 약국, 소매 약국, 온라인 약국)

조사 대상 기업 사례(총 32개사)

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Janssen Pharmaceuticals(Johnson & Johnson)
  • Merck & Co., Inc.
  • MoonLake Immunotherapeutics
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

관세 영향 계수

Global Industry Analysts는 본국, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 매출원가 증가, 수익성 하락, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사하고 있습니다.

Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.

2025년 4월 : 협상 단계

이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.

2025년 7월 : 최종 관세 재설정

고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.

상호 및 양자 간 무역과 관세의 영향 분석:

미국 <> 중국 <> 멕시코 <> 캐나다 <> EU <> 일본 <> 인도 <> 기타 176개국

업계 최고의 이코노미스트 : Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.06.12

Global Psoriatic Arthritis Treatment Market to Reach US$16.3 Billion by 2030

The global market for Psoriatic Arthritis Treatment estimated at US$10.8 Billion in the year 2024, is expected to reach US$16.3 Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Biologics, one of the segments analyzed in the report, is expected to record a 6.3% CAGR and reach US$9.5 Billion by the end of the analysis period. Growth in the Non-biologics segment is estimated at 8.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.9 Billion While China is Forecast to Grow at 11.0% CAGR

The Psoriatic Arthritis Treatment market in the U.S. is estimated at US$2.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Psoriatic Arthritis Treatment" Market - Is the Era of Personalized Autoimmune Care Here?

Is Rising Disease Awareness Catalyzing Early Diagnosis and Treatment?

Psoriatic arthritis (PsA), a chronic inflammatory disease associated with psoriasis, is gaining recognition due to rising public and clinical awareness. Previously underdiagnosed or misdiagnosed, PsA is now being identified earlier, leading to timely therapeutic intervention and better outcomes. Increased awareness campaigns by healthcare organizations, dermatology clinics, and rheumatology societies are encouraging patients to report early joint discomfort or stiffness. Innovations in imaging and biomarker testing are enhancing diagnostic accuracy, while patient support communities are driving proactive care-seeking behavior. These factors are boosting early-stage treatment initiation, a crucial determinant of disease progression and quality of life.

Are Biologic and Targeted Therapies Transforming the Treatment Landscape?

The PsA treatment market has undergone a dramatic shift with the advent of biologics and small molecule inhibitors. TNF inhibitors, IL-17 and IL-23 inhibitors, and JAK inhibitors have emerged as frontline therapies, offering more targeted immunomodulation with improved efficacy and reduced systemic side effects. As biologics become more affordable and biosimilars enter the market, access is expanding across different geographies. Additionally, oral therapies such as PDE4 inhibitors are providing more convenient options for patients unwilling or unable to use injectable biologics. Clinical guidelines are increasingly supporting early biologic use to prevent joint damage, further pushing demand for advanced therapies.

Is Patient-Centered Care Driving Treatment Customization?

Psoriatic arthritis manifests differently among patients, making personalized treatment strategies critical. Shared decision-making is gaining traction in rheumatology practices, with patients and providers working together to select therapies based on comorbidities, lifestyle preferences, and treatment goals. Digital health tools are helping track symptoms, adherence, and response to medication, enabling real-time adjustments to care plans. Patients are also more educated about potential side effects, access programs, and alternative treatment options. This shift toward individualized therapy and improved access support services is enhancing treatment satisfaction and persistence, reinforcing demand for diverse therapeutic offerings.

The Growth in the Psoriatic Arthritis Treatment Market Is Driven by Several Factors…

The growth in the psoriatic arthritis treatment market is driven by several factors including therapeutic innovation, broader diagnosis, and changing patient engagement dynamics. Technologically, the development of new biologic pathways and oral agents is expanding treatment options with higher efficacy and specificity. End-use growth is observed in rheumatology clinics and specialty pharmacies that provide coordinated care and insurance navigation. Consumer trends are shifting toward informed, proactive disease management with greater use of digital health tools and participation in clinical trials. Further, increasing pharmaceutical investments in autoimmune drug pipelines, rising prevalence in developed markets, and stronger reimbursement frameworks are reinforcing the expansion of PsA treatment offerings worldwide.

SCOPE OF STUDY:

The report analyzes the Psoriatic Arthritis Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Biologics, Non-biologics, Combination Therapy); Product Type (Prescription & Over-the-Counter); Administration Route (Parenteral, Oral); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Alvotech
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Biogen Inc.
  • Bristol-Myers Squibb Company
  • Celltrion, Inc.
  • Currax Pharmaceuticals LLC
  • Eli Lilly and Company
  • Janssen Pharmaceuticals (Johnson & Johnson)
  • Merck & Co., Inc.
  • MoonLake Immunotherapeutics
  • Novartis AG
  • Pfizer Inc.
  • Samsung Bioepis
  • Sanofi
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Impact of Covid-19 and a Looming Global Recession
    • Psoriatic Arthritis Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Autoimmune and Inflammatory Disorders Spurs Therapy Demand
    • Biologic Drug Innovations Propel Market Growth Through Improved Patient Outcomes
    • Shift Toward Early Diagnosis and Intervention Strengthens Use of DMARDs and Biologics
    • Expansion of Specialty Clinics and Rheumatology Centers Increases Treatment Accessibility
    • Pipeline Advancements in Oral Small Molecule Drugs Generate Competitive Momentum
    • Patient Demand for Targeted Therapies with Fewer Side Effects Drives R&D Investment
    • Integration of Companion Diagnostics Enhances Personalized Treatment Approaches
    • Telehealth Growth Expands Access to Specialist Care and Prescription Services
    • Improved Patient Education and Disease Awareness Strengthens Adherence to Long-Term Therapies
    • Health Insurance Expansion and Reimbursement Support Promote Biologic Drug Uptake
    • Rise of Combination Therapies Creates New Revenue Streams for Pharma Players
    • Ongoing Clinical Trials Exploring Novel Mechanisms of Action Expand Treatment Options
    • Increased Physician Familiarity with New Drug Classes Accelerates Prescribing Behavior
    • Regulatory Approvals Across Emerging Markets Expand Access to Advanced Therapies
    • Partnerships Between Pharma Companies and Advocacy Groups Drive Patient Support Programs
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Psoriatic Arthritis Treatment Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Psoriatic Arthritis Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Non-biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Combination Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Combination Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Prescription & Over-the-Counter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Prescription & Over-the-Counter by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Prescription & Over-the-Counter by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 68: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 74: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Psoriatic Arthritis Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: France Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: France 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 116: Germany Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Germany Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Germany 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 125: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Italy Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 128: Italy Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Italy Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Italy 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 131: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 134: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: UK Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 137: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: UK Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 140: UK Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: UK Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: UK 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 143: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Spain Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 146: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Spain Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 149: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Spain Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 152: Spain Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Spain Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Spain 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 155: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Russia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 158: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Russia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 161: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Russia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 164: Russia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Russia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Russia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Europe Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Europe 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 182: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 194: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Australia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 197: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Australia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 200: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Australia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 203: Australia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Australia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Australia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 206: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: India Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: India 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 209: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: India Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: India 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 212: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: India Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: India 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 215: India Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: India Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: India 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 218: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: South Korea Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 221: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: South Korea Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 224: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: South Korea Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 227: South Korea Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: South Korea Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: South Korea 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 230: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 233: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Asia-Pacific Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 242: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 243: Latin America Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 245: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Latin America Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 248: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Latin America Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 251: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Latin America Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 254: Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Latin America Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 257: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Argentina Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 260: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Argentina Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 263: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Argentina Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 266: Argentina Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Argentina Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Argentina 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 269: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Brazil Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 272: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Brazil Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 275: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Brazil Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 278: Brazil Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Brazil Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Brazil 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 281: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Mexico Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 284: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Mexico Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 287: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Mexico Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 290: Mexico Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Mexico Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: Mexico 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 293: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Latin America Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Latin America 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 305: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 306: Middle East Historic Review for Psoriatic Arthritis Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 308: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Middle East Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 311: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Middle East Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 313: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 314: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Middle East Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 316: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 317: Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Middle East Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 319: Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 320: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 321: Iran Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 322: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 323: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 324: Iran Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 325: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 326: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 327: Iran Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 328: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 329: Iran Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 330: Iran Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 331: Iran 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 332: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 333: Israel Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 334: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 335: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 336: Israel Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 337: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 338: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 339: Israel Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 340: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 341: Israel Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 342: Israel Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 343: Israel 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 344: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 345: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 346: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 347: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 348: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 349: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 351: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 352: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 354: Saudi Arabia Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 355: Saudi Arabia 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 356: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 357: UAE Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 358: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 359: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 360: UAE Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 361: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 362: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 363: UAE Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 364: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 365: UAE Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 366: UAE Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 367: UAE 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 368: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 369: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 370: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 371: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 372: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 373: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 375: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 376: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 378: Rest of Middle East Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 379: Rest of Middle East 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Psoriatic Arthritis Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 380: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 381: Africa Historic Review for Psoriatic Arthritis Treatment by Drug Class - Biologics, Non-biologics and Combination Therapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 382: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Drug Class - Percentage Breakdown of Value Sales for Biologics, Non-biologics and Combination Therapy for the Years 2015, 2025 & 2030
    • TABLE 383: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 384: Africa Historic Review for Psoriatic Arthritis Treatment by Product Type - Prescription & Over-the-Counter Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 385: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Product Type - Percentage Breakdown of Value Sales for Prescription & Over-the-Counter for the Years 2015, 2025 & 2030
    • TABLE 386: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 387: Africa Historic Review for Psoriatic Arthritis Treatment by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 388: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
    • TABLE 389: Africa Recent Past, Current & Future Analysis for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 390: Africa Historic Review for Psoriatic Arthritis Treatment by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 391: Africa 15-Year Perspective for Psoriatic Arthritis Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제